Pacific Biosciences of California, Inc. (PACB) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 68.81M USD | Liabilities, Current |
| Cash and equivalents | 61.00M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 31.10M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 61.08M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $68.81M | $61.00M | (m) | $31.10M | $61.08M | (m) |
| 2026-03-31 | (m) | $65.36M | $56.27M | (m) | $29.35M | $51.02M | (m) |
| 2025-12-31 | (m) | $72.83M | $63.71M | (m) | $35.45M | $49.28M | (m) |
| 2025-09-30 | (m) | $63.21M | $56.47M | (m) | $30.62M | $53.15M | (m) |
| 2025-06-30 | (m) | $59.75M | $54.80M | (m) | $32.26M | $53.84M | (m) |
| 2025-03-31 | (m) | $66.60M | $58.51M | (m) | $31.64M | $54.01M | (m) |
| 2024-12-31 | (m) | $66.30M | $55.37M | (m) | $27.52M | $58.76M | (m) |
| 2024-09-30 | (m) | $60.00M | $77.98M | (m) | $29.38M | $65.74M | (m) |
| 2024-06-30 | (m) | $78.39M | $99.53M | (m) | $32.43M | $68.59M | (m) |
| 2024-03-31 | (m) | $72.95M | $76.65M | (m) | $30.32M | $67.34M | (m) |
| 2023-12-31 | $681.71M | $95.03M | $179.91M | $465.18M | $36.62M | $56.68M | 7.17× |
| 2023-09-30 | (m) | $183.96M | $385.65M | (m) | $30.49M | $68.26M | (m) |
| 2023-06-30 | (m) | $271.41M | $209.29M | (m) | $24.03M | $67.61M | (m) |
| 2023-03-31 | (m) | $265.67M | $353.83M | (m) | $29.59M | $61.95M | (m) |
| 2022-12-31 | $908.63M | $263.33M | $325.09M | $564.75M | $18.79M | $50.38M | 3.45× |
| 2022-09-30 | $997.50M | $81.65M | $304.43M | $670.32M | $22.76M | $43.49M | 12.22× |
| 2022-06-30 | $1.02B | $84.40M | $310.44M | $687.19M | $27.06M | $36.12M | 12.14× |
| 2022-03-31 | $1.11B | $61.01M | $428.57M | $651.21M | $27.85M | $29.63M | 18.16× |
| 2021-12-31 | $1.08B | $71.71M | $460.73M | $595.06M | $24.24M | $24.60M | 15.06× |
| 2021-09-30 | $854.33M | $55.61M | $425.39M | $405.00M | $23.95M | $18.28M | 15.36× |
| 2021-06-30 | $1.05B | $45.43M | $459.79M | $574.30M | $19.94M | $17.98M | 23.20× |
| 2021-03-31 | $1.18B | $33.74M | $932.40M | $236.28M | $12.91M | $16.27M | 35.02× |
| 2020-12-31 | $353.65M | $38.50M | $81.61M | $255.21M | $16.84M | $14.23M | 9.19× |
| 2020-09-30 | $233.69M | $130.27M | $69.03M | $152.86M | $11.81M | $15.94M | 1.79× |
| 2020-06-30 | $135.72M | $130.86M | $43.34M | $81.03M | $11.35M | $16.77M | 1.04× |
| 2020-03-31 | $178.98M | $131.97M | $68.86M | $102.79M | $7.33M | $16.12M | 1.36× |
| 2020-01-01 | (m) | (m) | (m) | (m) | $15.23M | (m) | (m) |
| 2019-12-31 | $75.35M | $49.15M | $29.63M | $30.45M | $15.27M | $13.31M | 1.53× |
| 2019-09-30 | $73.75M | $50.69M | $33.08M | $30.70M | $9.97M | $15.07M | 1.45× |
| 2019-06-30 | $92.20M | $49.45M | $30.36M | $49.72M | $12.12M | $17.40M | 1.86× |
| 2019-03-31 | $99.03M | $45.10M | $38.20M | $53.54M | $7.28M | $19.65M | 2.20× |
| 2018-12-31 | $109.46M | $26.88M | $18.84M | $82.02M | $8.60M | $17.88M | 4.07× |
| 2018-09-30 | $129.85M | $21.65M | $38.06M | $85.38M | $6.40M | $19.69M | 6.00× |
| 2018-06-30 | $77.56M | $22.26M | $23.06M | $47.05M | $7.45M | $23.44M | 3.48× |
| 2018-03-31 | $93.44M | $24.95M | $25.46M | $59.53M | $8.45M | $25.93M | 3.75× |
| 2017-12-31 | $77.95M | $28.64M | $16.51M | $48.01M | $13.43M | $23.07M | 2.72× |
| 2017-09-30 | $96.51M | $30.29M | $25.93M | $61.68M | $8.90M | $18.20M | 3.19× |
| 2017-06-30 | $130.15M | $35.69M | $36.48M | $84.14M | $9.53M | $17.27M | 3.65× |
| 2017-03-31 | (m) | $35.44M | $28.98M | (m) | $10.44M | $15.35M | (m) |
| 2016-12-31 | (m) | $33.77M | $16.77M | (m) | $11.42M | $15.63M | (m) |
| 2016-09-30 | (m) | $32.11M | $22.79M | (m) | $11.76M | $16.47M | (m) |
| 2016-06-30 | (m) | $33.81M | $24.78M | (m) | $10.43M | $14.20M | (m) |
| 2016-03-31 | (m) | $32.01M | $20.08M | (m) | $8.01M | $12.16M | (m) |
| 2015-12-31 | (m) | $38.18M | $33.63M | (m) | $5.25M | $10.96M | (m) |
| 2015-09-30 | (m) | $38.75M | $27.21M | (m) | $4.16M | $11.62M | (m) |
| 2015-06-30 | (m) | $39.02M | $25.93M | (m) | $3.95M | $11.98M | (m) |
| 2015-03-31 | (m) | $38.41M | $30.27M | (m) | $5.29M | $13.46M | (m) |
| 2014-12-31 | (m) | $31.49M | $36.45M | (m) | $3.41M | $11.34M | (m) |
| 2014-09-30 | (m) | $29.14M | $35.41M | (m) | $2.37M | $11.40M | (m) |
| 2014-06-30 | (m) | $27.97M | $28.20M | (m) | $4.25M | $9.44M | (m) |
| 2014-03-31 | (m) | $22.51M | $41.26M | (m) | $3.38M | $8.30M | (m) |
| 2013-12-31 | (m) | $22.55M | $26.36M | (m) | $2.75M | $10.05M | (m) |
| 2013-09-30 | (m) | $22.48M | $64.77M | (m) | $3.81M | $9.82M | (m) |
| 2013-06-30 | (m) | $15.09M | $40.83M | (m) | $4.10M | $10.28M | (m) |
| 2013-03-31 | (m) | $13.58M | $53.04M | (m) | $2.01M | $10.60M | (m) |
| 2012-12-31 | (m) | $14.74M | $46.54M | (m) | $2.82M | $9.59M | (m) |
| 2012-09-30 | (m) | $13.63M | $32.56M | (m) | $532.00K | $10.20M | (m) |
| 2012-06-30 | (m) | $14.93M | $33.62M | (m) | $3.37M | $10.27M | (m) |
| 2012-03-31 | (m) | $19.80M | $56.26M | (m) | $1.50M | $11.82M | (m) |
| 2011-12-31 | (m) | $19.38M | $58.87M | (m) | $4.56M | $15.52M | (m) |
| 2011-09-30 | (m) | $21.13M | $57.58M | (m) | $4.43M | $20.26M | (m) |
| 2011-06-30 | (m) | $21.46M | $54.51M | (m) | $5.44M | $19.55M | (m) |
| 2011-03-31 | (m) | (m) | $84.61M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $20.84M | $147.65M | (m) | $341.00K | $6.86M | (m) |
| 2010-09-30 | (m) | (m) | $62.72M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $90.14M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $89.23M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $78.46M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |